Mnemo Therapeutics and Institut Curie Announce Two Key Publications in Science Immunology Highlighting Novel Approach to Identify Unknown, Therapeutically Relevant Cancer-Specific Targets -Studies are ...
Mnemo Therapeutics, a biotech working to refine and improve CAR-T cells, has tapped former Bayer EVP Robert LaCaze as its new CEO, effective May 1. LaCaze wraps up more than six years at Bayer, where ...
Mnemo Therapeutics and Institut Curie Announce Two Key Publications in Science Immunology Highlighting Novel Approach to Identify Unknown, Therapeutically Relevant Cancer-Specific Targets -Studies are ...
CAR-T therapies are heating up, with two new approvals in the past year, but the drug class has been limited to blood cancers and can run into resistance issues. Mnemo Therapeutics thinks it has a ...
Financing led by Casdin Capital, Sofinnova Partners - initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing ...
Mnemo Therapeutics, a company specializing in cell therapy using chimeric antigen receptor T cells (CAR-Ts), has launched with $90 million in series A funding. Casdin Capital led the financing round.
PARIS, Nov. 30, 2022 /PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced the appointment of Christine Foster, Ph.D. to the role of ...
Objective: to clinically validate efficacy of a new form of immunotherapy utilizing CAR-T cells to target multiple difficult-to-treat tumors PARIS, June 13, 2022 /PRNewswire/ -- Mnemo Therapeutics, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results